Monday, January 23, 2012
Cubist Pharmaceuticals Inc., of Lexington, Mass., reported full-year 2011 revenues of $754 million and GAAP earnings of $33 million, or 52 cents per diluted share. For the fourth quarter, revenues of $213 million beat the $204 million analysts had expected, but GAAP earnings of $6.8 million, or 11 cents per share, were far below expectations because of Cubist's $415 million acquisition of Exton, Pa.-based Adolor Corp.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.